SALT LAKE CITY--(BUSINESS WIRE)--Fluoresentric, Inc. today announced the issuance of U.S. patent 9,139,882 to further protect the company’s pioneering five (5) minute DNA/RNA amplification technology, which makes all PCR instruments faster and more accurate.
“The patent protection, which Fluoresentric owns, is the cornerstone of the Company’s intellectual property portfolio,” states Wes Lang, Fluoresentric’s Chief Patent Counsel. This patent covers a “System and Method for High Resolution Analysis of Nucleic Acids to Detect Sequence Variations.”
This decision by the U.S. Patent Office provides broad intellectual property protection for Fluoresentric’s Xtreme Chain Reaction (XCR™) molecular diagnostics technology. XCR™ combines the best of Polymerase Chain Reaction (PCR) and isothermal testing methods eliminating their limitations, including primer dimers. XCR™, at 5 to 10 times faster than PCR, improves the ability to detect DNA and RNA targets as well as deliver high multiplex, and quantitative results.
“This establishes XCR’s discovery and performance as the single most important event in this industry's history since the discovery of PCR over 30 years ago,” states CEO William Olson. “Our award winning XCR™ technology has demonstrated more efficient DNA and RNA replication. This chemistry produces five (5) minute amplification times without compromise, demonstrates thermal cycling temperature flexibility, and allows a lower cost and greater speed, making accurate near-patient molecular testing an everyday occurrence. This points the way for the industry as we all work towards better, more affordable healthcare.”
Olson continues, “The added good news here is that U.S. 9,139,882 ties back to our original issued patent (U.S. 7,838,235) with a priority date of 2007, carving a broad stroke of ownership for DNA/RNA amplification across this multi-billion dollar industry.”
Recently Fluoresentric, Inc. established a wholly owned subsidiary, XCR Diagnostics (XCR Dx). The new Company has an exclusive license to the XCR™ technology in Human Diagnostics worldwide, clearing the path to FDA-cleared products in the near future.
“We have anticipated this news for some time,” says XCR Dx’s COO Mark Powelson. “This gives XCR Diagnostics the ability to compete in the emerging near patient market plus deliver a new technology driven product ladder to molecular diagnostics.” Powelson is tasked with leading the team in its development of the industry’s first low cost, handheld Portable Diagnostic System (PDS) capable of leveraging XCR™ 5 min amplification, delivering a <15-minute sample-to-result diagnostic to the near-patient testing market.
About XCR Diagnostics, Inc.
XCR Diagnostics Inc. (XCR Dx), a Fluoresentric Inc. company, is a start-up instrument provider advancing near patient hand-held molecular instrumentation, sample preparation and detection chemistry in regulated human diagnostic markets, domestically and internationally. The Company is positioned to deliver the first sub 15-minute diagnostic test system to the market in 2016. The combination of small portable platforms and revolutionary molecular reagents enables XCR Diagnostics to dramatically trim test times and reduce healthcare costs, with a vision to deliver hyper-accurate molecular diagnostics testing near patient at point of care.
About Fluoresentric, Inc.
Fluoresentric Inc., an Intellectual Property company, is positioned to monetize its XCR™ technology portfolio globally. With strong intellectual property initially in molecular amplification, the Company has expanded its intellectual property collection into instrumentation, sample prep and other application chemistries. Fluoresentric’s vision is to apply the Company’s intellectual property to an extensive set of commercial opportunities resulting in better and faster results processing for healthcare and other industries worldwide.